Table 1.
Clinical summary for the three patient groups with prostate cancer including imaging and histopathology findings.
| Feature | MRI+/PET+ | MRI+/PET− | MRI−/PET+ | |
|---|---|---|---|---|
| Characteristics |
Number of patients
Age (mean ± SD) in years |
9 * 64.1 ± 6.2 |
2 57 ± 9.9 |
7 63.3 ± 6.6 |
| PSA (mean ± SD) in ng/mL | 13 ± 17.5 | 2.8 ± 2.7 | 8.9 ± 3.3 | |
| MRI (PI-RADS score) | 4 (n = 2) 5 (n = 7) |
4 (n = 2) | 1 (n = 1) 2 (n = 5) 3 (n = 1) # |
|
| PSMA PET/CT (lesion absent or present) | Present | Absent | Present | |
| Surgical pathology | ISUP score | 2 (n = 1) 3 (n = 4) 5 (n = 3) |
2 (n = 2) | 2 (n = 2) 3 (n = 3) 4 (n = 1) 5 (n = 1) |
| Pathological stage | pT2 (n = 2) pT3a (n = 4) pT3b (n = 3) |
pT2 (n = 2) | pT2 (n = 3) pT3a (n = 3) pT3b (n = 1) |
|
| Positive margins, n(%) | 5 (55%) | 1 (50%) | 2 (28%) |
Abbreviations: PSA—prostate-specific antigen, MRI—magnetic resonance imaging, PSMA PET/CT—prostate-specific membrane antigen positron emission tomography/computed tomography, PI-RADS—Prostate Imaging Reporting and Data System, ISUP—International Society of Urological Pathology. * One patient had a PSA of 59 (outlier) and was placed on neoadjuvant androgen deprivation therapy, which led to no Gleason grades/ISUP score assigned for histopathology due to treatment effect. # PI-RADS 3 due to diffuse low signal changes within the prostate most likely due to prostatitis.